Effect of treatment interruption and intensification of antiretroviral therapy on health-related quality of life in patients with advanced HIV: A randomized, controlled trial

Medical Decision Making

Volumn 32, Issue 1, 2012, Pages 70-82

  Joyce, Vilija R ^a,b   Barnett, Paul G ^a,b   Chow, Adam ^a,b   Bayoumi, Ahmed M ^c   Griffin, Susan C ^d   Sun, Huiying ^e,f   Holodniy, Mark ^a   Brown, Sheldon T ^g   Kyriakides, Tassos C ^h   Cameron, D William ⁱ   Youle, Mike ^j   Sculpher, Mark ^d   Anis, Aslam H ^f,k   Owens, Douglas K ^a,l  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF YORK   (United Kingdom)

^e ST PAUL S HOSPITAL   (Canada)

^f Canadian HIV Trials Network   (Canada)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h VA Cooperative Studies Program Coordinating Center   (United States)

ⁱ OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^j ROYAL FREE HOSPITAL   (United Kingdom)

^k UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^l STANFORD UNIVERSITY   (United States)

more..

Author keywords

AIDS; highly active antiretroviral therapy; HIV; quality of life; randomized trial; treatment intensification; treatment interruption

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; MULTICENTER STUDY; PATIENT CARE; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM; UNITED STATES;

ADULT; ANTI-RETROVIRAL AGENTS; CANADA; CONTINUITY OF PATIENT CARE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GREAT BRITAIN; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 84856614791     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X10397615     Document Type: Conference Paper

References (50)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997 ; 337 (11). 725-33 (Pubitemid 27417971)
2. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998 ; 279 (6). 450-4 (Pubitemid 28082255)
3. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998 ; 338 (13). 853-60 (Pubitemid 28135961)
4. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000 ; 133 (1). 21-30 (Pubitemid 30432540)
5. Phillips AN, Staszewski S, Lampe F, et al. Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression. J Infect Dis. 2002 ; 186 (8). 1086-91 (Pubitemid 35177110)
6. Mocroft A, Ledergerber B, Viard JP, et al. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. J Infect Dis. 2004 ; 190 (11). 1947-56 (Pubitemid 39564700)
7. Sabin CA, Hill T, Lampe F, et al. Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. BMJ. 2005 ; 330 (7493). 695
8. Cozzi-Lepri A, Phillips AN, Clotet B, et al. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. AIDS. 2008 ; 22 (16). 2187-98
9. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. [December 1, 2009; cited October 19, 2010]. Available from: URL: http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf
10. Napravnik S, Edwards D, Stewart P, Stalzer B, Matteson E, Eron JJ. HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. J Acquir Immune Defic Syndr. 2005 ; 40 (1). 34-40 (Pubitemid 41233202)
11. Cozzi-Lepri A, Phillips AN, Ruiz L, et al. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS. 2007 ; 21 (6). 721-32 (Pubitemid 46568629)
12. Rottmann C, Miller V, Staszewski S. Mega-HAART: preliminary results and correlation with baseline resistance. Antivir Ther. 1999 ; 4 (Suppl 3). 93-4 (Pubitemid 29512124)
13. Miller V, Cozzi-Lepri A, Hertogs K, et al. HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort. Antivir Ther. 2000 ; 5 (1). 49-55 (Pubitemid 30261206)
14. Montaner JS, Harrigan PR, Jahnke N, et al. Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS. 2001 ; 15 (1). 61-9 (Pubitemid 32055780)
15. Kyriakides TC, Babiker A, Singer J, et al. An open-label randomized clinical trial of novel therapeutic strategies for HIV- infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial. Control Clin Trials. 2003 ; 24 (4). 481-500 (Pubitemid 36831050)
16. Holodniy M, Brown ST, Cameron DW, et al. OPTIMA Team. Results of antiretroviral treatment tnterruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA Trial. PLoS ONE. 2011 ;:
17. Revicki DA. Relationship between health utility and psychometric health status measures. Med Care. 1992 ; 30 (5 Suppl). MS274-82
18. Gold MR, Siegel JE, Russell LB, Weinstein MC Cost-Effectiveness in Health and Medicine. New York: Oxford University Press ; 1996 :
19. Burman WJ, Grund B, Roediger MP, Friedland G, Darbyshire J, Wu AW. The impact of episodic CD4 cell count-guided antiretroviral therapy on quality of life. J Acquir Immune Defic Syndr. 2008 ; 47 (2). 185-93 (Pubitemid 351172185)
20. Krentz HB, Gill MJ. The impact on health-related quality of life of treatment interruptions in HIV-1-infected patients. AIDS. 2003 ; 17 (4). 631-3 (Pubitemid 36293120)
21. Lawrence J, Hullsiek KH, Thackeray LM, et al. Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: final results of the CPCRA 064 study. J Acquir Immune Defic Syndr. 2006 ; 43 (2). 169-78 (Pubitemid 44454810)
22. Lawrence J, Mayers DL, Hullsiek KH, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med. 2003 ; 349 (9). 837-46 (Pubitemid 37025403)
23. Maserati R, Foli A, Tomasoni L, et al. Effects of structured treatment interruptions on metabolic, anthropometric, immunologic, and quality of life outcomes in HIV-positive adults on HAART. Curr HIV Res. 2007 ; 5 (3). 337-43 (Pubitemid 46785069)
24. Nuesch R, Gayet-Ageron A, Chetchotisakd P, et al. The impact of combination antiretroviral therapy and its interruption on anxiety, stress, depression and quality of life in Thai patients. Open AIDS J. 2009 ; 3: 38-45
25. Pogany K, van Valkengoed IG, Prins JM, et al. Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN). J Acquir Immune Defic Syndr. 2007 ; 44 (4). 395-400 (Pubitemid 46555373)
26. Powers AE, Marden SF, McConnell R, et al. Effect of long- cycle structured intermittent versus continuous HAART on quality of life in patients with chronic HIV infection. AIDS. 2006 ; 20 (6). 837-45 (Pubitemid 43731565)
27. Ruiz L, Paredes R, Gomez G, et al. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS. 2007 ; 21 (2). 169-78 (Pubitemid 46036924)
28. Skiest DJ, Krambrink A, Su Z, Robertson KR, Margolis DM. Improved measures of quality of life, lipid profile, and lipoatrophy after treatment interruption in HIV-infected patients with immune preservation: results of ACTG 5170. J Acquir Immune Defic Syndr. 2008 ; 49 (4). 377-83
29. Tuldra A, Fumaz CR, Ferrer MJ, et al. Psychological impact of structured treatment interruptions in patients with prolonged undetectable HIV-1 viral loads. AIDS. 2001 ; 15 (14). 1904-6 (Pubitemid 32939262)
30. Joyce VR, Barnett PG, Bayoumi AM, et al. Health-related quality of life in a randomized trial of antiretroviral therapy for advanced HIV disease. J Acquir Immune Defic Syndr. 2009 ; 50 (1). 27-36
31. Singer JD, Willet JB Applied Longitudinal Data Analysis. New York: Oxford University Press ; 2003 :
32. Fairclough DL Design and Analysis of Quality of Life Studies in Clinical Trials. Boca Raton, FL: Chapman & Hall/CRC ; 2002 :
33. Anis AH, Nosyk B, Sun H, et al. Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS- defining events and non-AIDS serious adverse events. J Acquir Immune Defic Syndr. 2009 ; 51 (5). 631-9
34. Protopopescu C, Marcellin F, Spire B, et al. Health-related quality of life in HIV-1-infected patients on HAART: a five-years longitudinal analysis accounting for dropout in the APROCO-COPILOTE cohort (ANRS CO-8). Qual Life Res. 2007 ; 16 (4). 577-91 (Pubitemid 46474949)
35. Wu AW, Jacobson KL, Frick KD, et al. Validity and responsiveness of the Euroqol as a measure of health-related quality of life in people enrolled in an AIDS clinical trial. Qual Life Res. 2002 ; 11 (3). 273-82 (Pubitemid 34553507)
36. Revicki DA, Moyle G, Stellbrink HJ, Barker C. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir- zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group. AIDS. 1999 ; 13 (7). 851-8 (Pubitemid 29224589)
37. Cohen C, Revicki DA, Nabulsi A, Sarocco PW, Jiang P. A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. Advanced HIV Disease Ritonavir Study Group. AIDS. 1998 ; 12 (12). 1495-502 (Pubitemid 28369650)
38. Cohen CJ, Clumeck N, Molina JM, et al. Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen. J Acquir Immune Defic Syndr. 2004 ; 37 (1). 1140-6 (Pubitemid 39166648)
39. Huang IC, Wu AW, Finnern HW, Thijs H, Gathe JC, Fairclough DL. Health-related quality of life and tolerability in treatment-experienced HIV-1-infected patients on tipranavir versus comparator regimens. Antivir Ther. 2008 ; 13 (1). 15-25 (Pubitemid 351551686)
40. Preau M, Leport C, Salmon-Ceron D, et al. Health-related quality of life and patient-provider relationships in HIV-infected patients during the first three years after starting PI-containing antiretroviral treatment. AIDS Care. 2004 ; 16 (5). 649-61 (Pubitemid 38918097)
41. Braithwaite RS, Goulet J, Kudel I, Tsevat J, Justice AC. Quantifying the decrement in utility from perceived side effects of combination antiretroviral therapies in patients with HIV. Value Health. 2008 ; 11 (5). 975-9
42. Tsevat J, Sherman SN, McElwee JA, et al. The will to live among HIV-infected patients. Ann Intern Med. 1999 ; 131 (3). 194-8 (Pubitemid 29365002)
43. Coleman CL. Spirituality and sexual orientation: relationship to mental well-being and functional health status. J Adv Nurs. 2003 ; 43 (5). 457-64 (Pubitemid 37260235)
44. Cotton S, Puchalski CM, Sherman SN, et al. Spirituality and religion in patients with HIV/AIDS. J Gen Intern Med. 2006 ; 21 (Suppl 5). S5-13
45. Cotton S, Tsevat J, Szaflarski M, et al. Changes in religiousness and spirituality attributed to HIV/AIDS: are there sex and race differences?. J Gen Intern Med. 2006 ; 21 (Suppl 5). S14-20
46. Mrus JM, Sherman KE, Leonard AC, Sherman SN, Mandell KL, Tsevat J. Health values of patients coinfected with HIV/hepatitis C: are two viruses worse than one?. Med Care. 2006 ; 44 (2). 158-66 (Pubitemid 43755467)
47. Vidrine DJ, Amick BC, Gritz ER, Arduino RC. Functional status and overall quality of life in a multiethnic HIV-positive population. AIDS Patient Care STDS. 2003 ; 17 (4). 187-97 (Pubitemid 36444008)
48. Feeny D, Blanchard C, Mahon JL, et al. Comparing community- preference-based and direct standard gamble utility scores: evidence from elective total hip arthroplasty. Int J Technol Assess Health Care. 2003 ; 19 (2). 362-72 (Pubitemid 36818679)
49. Feeny D, Furlong W, Saigal S, Sun J. Comparing directly measured standard gamble scores to HUI2 and HUI3 utility scores: group- and individual-level comparisons. Soc Sci Med. 2004 ; 58 (4). 799-809 (Pubitemid 37524002)
50. Rashidi AA, Anis AH, Marra CA. Do visual analogue scale (VAS) derived standard gamble (SG) utilities agree with Health Utilities Index utilities? A comparison of patient and community preferences for health status in rheumatoid arthritis patients. Health Qual Life Outcomes. 2006 ; 4: 25